| Company: Oncolytics Biotech Inc. Presenter: Dr. Brad Thompson, Chairman, President & CEO Date: 22-June-2016 Occasion: Richmond Club Lunch, Toronto Length: 00:19:39 |
 |
Oncolytics Biotech Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers.REOLYSIN® has been utilized in nearly thirty clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a broad range of cancer indications.